Drug Profile
Raxibacumab - Emergent BioSolutions
Alternative Names: ABthrax; PAmAbLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Human Genome Sciences
- Class Antibacterials; Antitoxins; Monoclonal antibodies
- Mechanism of Action Anthrax toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anthrax
Most Recent Events
- 03 Oct 2017 Emergent BioSolutions acquires raxibacumab from GlaxoSmithKline
- 19 Jul 2017 Emergent BioSolutions enters into an agreement with GlaxoSmithKline to acquire raxibacumab
- 01 Aug 2014 GlaxoSmithKline plans a phase IV post-exposure study for Anthrax prevention and treatment in USA (NCT02177721)